HomeCompareVRNA vs ADC

VRNA vs ADC: Dividend Comparison 2026

VRNA yields 1.87% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $156.5K in total portfolio value
10 years
VRNA
VRNA
● Live price
1.87%
Share price
$106.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$211.14
Full VRNA calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — VRNA vs ADC

📍 ADC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRNAADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRNA + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRNA pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRNA
Annual income on $10K today (after 15% tax)
$159.01/yr
After 10yr DRIP, annual income (after tax)
$179.47/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,498.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRNA + ADC for your $10,000?

VRNA: 50%ADC: 50%
100% ADC50/50100% VRNA
Portfolio after 10yr
$100.7K
Annual income
$40,504.22/yr
Blended yield
40.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

VRNA
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Price Target
$75.73
-29.2% upside vs current
Range: $26.00 — $170.00
Altman Z
111.3
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRNA buys
0
ADC buys
0
No recent congressional trades found for VRNA or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRNAADC
Forward yield1.87%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$22.4K$178.9K
Annual income after 10y$211.14$80,797.29
Total dividends collected$2.0K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$75.73$81.06

Year-by-year: VRNA vs ADC ($10,000, DRIP)

YearVRNA PortfolioVRNA Income/yrADC PortfolioADC Income/yrGap
1← crossover$10,887$187.07$10,990$580.36$103.00ADC
2$11,840$190.34$12,301$860.26$461.00ADC
3$12,862$193.45$14,104$1,298.62$1.2KADC
4$13,958$196.41$16,691$2,008.16$2.7KADC
5$15,135$199.21$20,580$3,205.09$5.4KADC
6$16,396$201.87$26,754$5,330.02$10.4KADC
7$17,748$204.38$37,196$9,345.14$19.4KADC
8$19,197$206.77$56,244$17,523.09$37.0KADC
9$20,750$209.02$94,286$35,736.21$73.5KADC
10$22,414$211.14$178,949$80,797.29$156.5KADC

VRNA vs ADC: Complete Analysis 2026

VRNAStock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Full VRNA Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this VRNA vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRNA vs SCHDVRNA vs JEPIVRNA vs OVRNA vs KOVRNA vs MAINVRNA vs NNNVRNA vs EPRTVRNA vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.